JamesLewisPoolMD

PubMed

• 7 citations
  Clinical role of direct renin inhibition in hypertension.
  Addison A. Taylor, James L. Pool> ;American Journal of Therapeutics. 2012 May 1
• 19 citations
  Effect of a Physician Uncertainty Reduction Intervention on Blood Pressure in Uncontrolled Hypertensives—A Cluster Randomized Trial
  David J. Hyman, Valory N. Pavlik, Anthony J. Greisinger, Wenyaw Chan, Jose Bayona, Carol L. Mansyur, Victor Simms, James L. Pool> ;Journal of General Internal Medicine. 2012 Apr 1
• 25 citations
  Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose.
  Todd S. Perlstein, Robert R. Henry, Kieren J. Mather, Michael R. Rickels, Nicola Abate, Scott M. Grundy, Yabing Mai, Jeanine Albu, Jennifer B. Marks, James L. Pool, Ma...> ;Clinical Science. 2011 Aug 24
• 21 citations
  Disability hate crime and targeted violence and hostility: A mental health and discrimination perspective
  Sarah Clement, Elaine Brohan, Liz Sayce, James L. Pool, Graham Thornicroft> ;Journal of Mental Health. 2011 May 16
• 18 citations
  Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hyper...
  Keith C. Ferdinand, James L. Pool, Richard Weitzman, Das Purkayastha, Raymond R. Townsend> ;Journal of Clinical Hypertension. 2011 May 1
• 13 citations
  AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk
  Vincent E. Friedewald, Joel S. Bennett, J. Paul Christo, James L. Pool, James M. Scheiman, Lee S. Simon, Vibeke Strand, William B. White, Gary W. Williams, William C. ...> ;The American Journal of Cardiology. 2010 Sep 15
• 39 citations
  Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate.
  Lawrence E. Mallette, Adrian D. Leblanc, James L. Pool, Jeffrey I. Mechanick> ;Journal of Bone and Mineral Research. 2009 Dec 3
• 15 citations
  Does Reducing Physician Uncertainty Improve Hypertension Control? Rationale and Methods
  Valory N. Pavlik, Anthony J. Greisinger, James L. Pool, Paul Haidet, David J. Hyman> ;Circulation. Cardiovascular Quality and Outcomes. 2009 May 1
• 4 citations
  The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive ad...
  James L. Pool, Robert Glazer, Nora Crikelair, Drew Griffin Levy> ;Clinical Drug Investigation. 2009 Jan 1
• 4 citations
  The Editor's Roundtable: Endothelial dysfunction in cardiovascular disease.
  Vincent E. Friedewald, Thomas D. Giles, James L. Pool, Clyde W. Yancy, William C. Roberts> ;The American Journal of Cardiology. 2008 Aug 15
• 6 citations
  A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension
  Suzanne Oparil, Nicola Abate, Erluo Chen, Mark A. Creager, Vincent A. Galet, Gang Jia, Stevo Julius, A. Lerman, Paulette A. Lyle, James L. Pool, Andrew M. Tershakovec> ;Current Medical Research and Opinion. 2008 Mar 6
• 35 citations
  Direct renin inhibition: focus on aliskiren.
  James L. Pool> ;Journal of Managed Care Pharmacy. 2007 Oct 1
• The editor's roundtable: concurrent hypertension and dyslipidemia.
  Vincent E. Friedewald, Peter B. Jones, Norman M Kaplan, James L. Pool, William C. Roberts> ;The American Journal of Cardiology. 2007 Jan 1
• 167 citations
  Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan
  James L. Pool, Roland E. Schmieder, Michel Azizi, Jean-Claude Aldigier, Andrzej Januszewicz, Walter Zidek, Yanntong Chiang, Andrew Satlin> ;American Journal of Hypertension. 2007 Jan 1
• 69 citations
  Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-...
  James L. Pool, Robert Glazer, Myron H. Weinberger, Roxanne Alvarado, Jie Huang, Alan Graff> ;Clinical Therapeutics. 2007 Jan 1
• 4 citations
  Clinical pharmacology of antihypertensive therapy.
  Addison A. Taylor, James L. Pool> ;Seminars in Nephrology. 2005 Jul 1
• 16 citations
  Is it time to move to multidrug combinations
  James L. Pool> ;American Journal of Hypertension. 2003 Nov 1
• 49 citations
  Comparative Effects of Candesartan Cilexetil and Amlodipine in Patients With Mild Systemic Hypertension
  Robert A. Kloner, Myron Weinberger, James L. Pool, Steven G. Chrysant, Rajesh Prasad, Susan M. Harris, Teresa M. Zyczynski, Nancy Kline Leidy, Eric L. Michelson> ;The American Journal of Cardiology. 2001 Mar 15
• 17 citations
  Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
  James L. Pool, Roger Kirby> ;International Urology and Nephrology. 2001 Jan 1
• 4 citations
  Current Concepts of Pharmacotherapy in Hypertension - Alpha-Adrenergic Blocking Drugs: Evolving Role in Clinical Medicine.
  Domenic A. Sica, James L. Pool> ;Journal of Clinical Hypertension. 2000 Mar 1
• 9 citations
  Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects.
  Addison A. Taylor, Alexander M. M. Shepherd, William Polvino, Roberto Mangoo-Karim, Kevin D. Ballard, Sarat Sunthornyothin, Robert R. Luther, James L. Pool> ;American Journal of Hypertension. 1999 Sep 1
• 10 citations
  Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study.
  Addison A. Taylor, Roberto Mangoo-Karim, Kevin D. Ballard, Robert R. Luther, James L. Pool> ;Journal of Clinical Pharmacology. 1999 May 1
• 49 citations
  Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
  James L. Pool, Robert Glazer, Yanntong Chiang, M Gatlin> ;Journal of Human Hypertension. 1999 Apr 1
• 35 citations
  Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II—receptor blocker
  James L. Pool, Suzanne Oparil, Thomas Hedner, Robert Glazer, Pascale Oddou-Stock, Allen Hester> ;Clinical Therapeutics. 1998 Nov 1
• 8 citations
  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension
  Yves Lacourcière, James L. Pool, Laura P. Svetkey, Alan H. Gradman, Pierre Larochelle, Jacques de Champlain, William B. Smith> ;American Journal of Hypertension. 1998 Apr 1
• Join now to see all